Actionable news
0
All posts from Actionable news
Actionable news in AVXL: Anavex Life Sciences Corp.,

Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016

Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016

Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events

NEW YORK, July 24, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced data from the first of two posters at the Alzheimer's Association International Conference(R) (AAIC) 2016.

Data presented in the first poster highlights the evaluation of a maximum tolerated dose (MTD) of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer's patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks. The second poster will present efficacy data through 31 weeks.

"ANAVEX 2-73 data presented today is prerequisite information in order to progress into Phase 2/3 placebo controlled studies," said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities' Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex's Scientific Advisory Board. "ANAVEX 2-73's specific molecular biology, combined with its observed favorable safety and tolerability profile makes it a very interesting candidate to explore in further clinical trials of different neurological diseases."

Dose-response analysis indicates a cognitive benefit associated with ANAVEX 2-73 (both MMSE and EEG/ERP improved significantly at 5 weeks of treatment). Low-High dose was statistically significant to affect MMSE- and ERP- scores with MMSE-...


More